Monday, November 24, 2014
Well-known Life Science Executive Kevin M. Smith to Retire as President/CEO of Colorado Institute for Drug, Device and Diagnostic Development; Search Committee Formed to Hire Smith’s Successor
The Colorado Institute for Drug, Device and Diagnostic Development (CID4) has begun a search for a new Executive Director, as Kevin M. Smith leaves as part of a planned retirement. Mr. Smith will remain with CID4 through February 2015 to ensure a smooth and successful transition for CID4’s new leader.
Aurora, CO November 24, 2014 – Kevin M. Smith, President and CEO of the Colorado Institute for Drug, Device and Diagnostic Development (CID4) since 2010, will retire from his position as Chief Executive Officer on December 31, 2014. The announcement is made by Steve Orndorff, PhD, Chairman of the CID4 Board and President & CEO of MicroBiome Therapeutics, who says the CID4 Board has formed a search committee and that Smith will be available through February 2015 to assist in a smooth transition for the new Executive Director.
“With the ongoing changes in the healthcare and life science sectors, CID4 is revisiting how it can best support our industry,” Orndorff said. “CID4 is well positioned for its future and we believe the new Executive Director position will strengthen our alignment with the State of Colorado in our mutual quest to create new jobs and business opportunities within the dynamic life science sector of advanced industries.”
All inquiries should be directed to the ‘CID4 Search Committee’ at firstname.lastname@example.org. The deadline for applications is December 20, 2014. Principals only need apply, please.
About Kevin M. Smith, CID4 President/CEO
Smith was part of the team that founded CID4 in 2009. Prior to CID4, Smith was President of Gambro, Inc., the U.S. holding company for Gambro AB, the Sweden-based medical device and healthcare services company. He started his career with Arthur Young in New York and was a partner with Ernst & Young, leading the development of their Colorado life science practice at the time he left to join Gambro.
“While I will no longer be leading CID4, I will stay active in the Colorado life science community through my Board responsibilities at the Colorado BioScience Association, Donor Alliance and AlloSource, my service on the Centura Health Audit and Corporate Responsibility Committee and my investment activities at KMG Capital Partners LLC,” Smith said. “CID4’s success is grounded in the excellent technologies that are being developed in Colorado. We have invested approximately $3 million into nine early stage companies. Those firms have gone on to create 85 new jobs and raise an additional $30 million to support the commercialization of their patient-focused technologies. I am proud to have played a role in this process.”
Founded in 2009, the Colorado Institute for Drug, Device and Diagnostic Development (CID4) is a 501(c)(3) not-for-profit charitable organization whose mission is to advance the Colorado bioscience ecosystem through company creation and job growth. Active business management and capital work in tandem to help bridge the gap between discovery and product development. CID4 works to identify, fund and actively manage emerging life science technologies. This aim is achieved via an ongoing technology solicitation process augmented by additional deal flow sourcing through networked relationships. Active due diligence is provided by CID4 management in consultation with members of the CID4 Technical and Business Advisory Committee. For more information visit http://CID4.com.
Kevin M. Smith, President/CEO CID4, http://CID4.com - email@example.com, (720) 859-4047
Maggie Chamberlin Holben, APR, http://www.absolutelypr.com - firstname.lastname@example.org, (303) 984-9801 or (303) 669-3558
Link to the PitchEngine social media release
Link to the PR.com posting